The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | The use of fibreoptic bronchoscopy in monitoring NSCLC success
Guillaume Eberst, MD, University Hospital of Besancon, Besancon, France, states fibreoptic bronchoscopy has no future role in monitoring recurrences and second cancers in patients with non-small cell lung cancer (NSCLC). In line with the IFCT study (NCT00198341), no significant difference was found in patients identified by screening with routine clinic visits or chest X-rays and fibreoptic bronchoscopy. It is necessary to perform longer, larger-scale studies assessing the efficacy of these screening techniques in detecting treatable recurrences and second cancers in patients at high risk of such events. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
